CSS
MRSN

Cubist Systematic Strategies’s Mersana Therapeutics MRSN Stock Holding History

Cubist Systematic Strategies’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,812
Closed -$64.8K – 3271
2024
Q4 		$64.8K Buy
+1,812
New +$93.7K ﹤0.01% 2756
2024
Q2 		– Sell
-9,566
Closed -$1.07M – 3647
2024
Q1 		$1.07M Buy
9,566
+4,940
+107% +$491K 0.01% 2111
2023
Q4 		$268K Buy
4,626
+2,196
+90% +$88.3K ﹤0.01% 2838
2023
Q3 		$77.2K Sell
2,430
-5,026
-67% -$239K ﹤0.01% 2972
2023
Q2 		$613K Sell
7,456
-4,982
-40% -$729K ﹤0.01% 2267
2023
Q1 		$1.28M Sell
12,438
-4,648
-27% -$652K 0.01% 1987
2022
Q4 		$2.5M Buy
17,086
+1,385
+9% +$234K 0.01% 1667
2022
Q3 		$2.65M Buy
15,701
+10,920
+228% +$1.77M 0.01% 1715
2022
Q2 		$552K Sell
4,781
-6,659
-58% -$626K ﹤0.01% 2987
2022
Q1 		$1.14M Buy
11,440
+6,948
+155% +$812K 0.01% 1932
2021
Q4 		$699K Buy
+4,492
New +$874K 0.01% 2195
2021
Q3 		– Sell
-809
Closed -$275K – 3091
2021
Q2 		$275K Buy
809
+574
+244% +$217K ﹤0.01% 2389
2021
Q1 		$95K Buy
235
+82
+54% +$39.8K ﹤0.01% 2653
2020
Q4 		$102K Sell
153
-1,220
-89% -$678K ﹤0.01% 2404
2020
Q3 		$639K Sell
1,373
-406
-23% -$205K 0.01% 1597
2020
Q2 		$1.04M Buy
1,779
+1,223
+220% +$418K 0.02% 1157
2020
Q1 		$81K Buy
556
+467
+525% +$81.6K ﹤0.01% 1940
2019
Q4 		$13K Sell
89
-85
-49% -$6.21K ﹤0.01% 2363
2019
Q3 		$7K Sell
174
-429
-71% -$31.2K ﹤0.01% 2160
2019
Q2 		$61K Buy
603
+33
+6% +$3.89K ﹤0.01% 2299
2019
Q1 		$75K Buy
570
+361
+173% +$45.4K ﹤0.01% 2045
2018
Q4 		$21K Buy
+209
New +$33.1K ﹤0.01% 1945
2018
Q3 		– Sell
-65
Closed -$29K – 2008
2018
Q2 		$29K Buy
+65
New +$28.5K ﹤0.01% 1691

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cubist Systematic Strategies's MRSN Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Mersana Therapeutics (MRSN) in Q1 2025, closing a stake of 1,812 shares — an estimated $64.8K sold.

Cubist Systematic Strategies first reported a position in MRSN in Q2 2018 and held it in 23 quarters. The position peaked at $2.65M in Q3 2022. 108 funds tracked by Wall St. Rank hold MRSN as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Mersana Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,812 Mersana Therapeutics shares in Q1 2025, an estimated $64.8K.
  • Cubist Systematic Strategies first reported a position in Mersana Therapeutics in Q2 2018 and held it in 23 quarters.
  • Cubist Systematic Strategies's Mersana Therapeutics position peaked at $2.65M in Q3 2022.
  • 108 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.